ArticleCureus2025
Non-occlusive Mesenteric Ischemia Following Transcatheter Aortic Valve Replacement: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Open superior mesenteric artery thrombectomy of dislodged aortic valve causing acute mesenteric ischemia.Journal of vascular surgery cases and innovative techniques · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-occlusive mesenteric ischemia (NOMI) is a rare complication after transcatheter aortic valve replacement (TAVR), with a poorly understood pathogenesis. We present the case of a 79-year-old female with a history of surgically repaired abdominal aortic aneurysm (AAA) and stable thoracic aortic aneurysm (TAA) who developed NOMI after TAVR, resulting in extensive bowel necrosis and patient mortality. Our case highlights the special attention that must be paid to patients with a history of endovascular interventions prior to TAVR due to the risk of postprocedural NOMI. We propose that NOMI after TAVR occurs from the reduction in cardiac output due to rapid pacing during valve deployment, resulting in worsening splanchnic hypoperfusion in patients with existing mesenteric vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.